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Brief Definit ive Report
Rheumatoid arthritis (RA) affects 0.5–1% of 
the population in most studied communities 
(Neovius et al., 2011). Today, the detection of 
prototypic autoantibodies, so-called ACPAs (anti-
citrullinated protein antibodies; Schellekens 
et al., 1998), is part of the diagnostic criteria for 
RA (Aletaha et al., 2010), and approximately 
two thirds of patients are seropositive (Klareskog 
et al., 2008). Typically, sera from ACPA+ RA pa-
tients contain antibodies toward several differ-
ent citrullinated autoantigens (Verpoort et al., 
2007; Snir et al., 2010). Anticitrulline antibodies 
often emerge before onset of disease (Rantapää-
Dahlqvist et al., 2003; Nielen et al., 2004; van de 
Stadt et al., 2011), and we have recently demon-
strated their accumulation in synovial fluid (i.e., 
active rheumatic joints) as compared with sera, 
suggesting that they are at least partly produced 
in the inflamed lesions (Snir et al., 2010). Col-
lectively, the anticitrulline immunity in RA pro-
vides an interesting and multifaceted case of 
potentially pathogenic humoral autoimmunity. 
To gain a more thorough understanding of the 
humoral aspect of this autoimmunity, we inves-
tigated the cellular and molecular basis of the 
production of antibodies to various citrullinated 
autoantigens in RA patients.
CORRESPONDENCE  
Vivianne Malmström: 
vivianne.malmstrom@ki.se 
OR 
Khaled Amara: 
Khaled.amara@ki.se
Abbreviations used: ACPA, 
anticitrullinated protein  
antibody; CCP, cyclic  
citrullinated peptide; CDR, 
complementarity-determining 
region; FWR, framework 
region; PEI, polyethylenimine; 
RA, rheumatoid arthritis; SHM, 
somatic hypermutation; SPR, 
surface plasmon resonance.
J. Steen and F. Murray contributed equally to this paper.
Monoclonal IgG antibodies generated  
from joint-derived B cells of RA patients 
have a strong bias toward citrullinated 
autoantigen recognition
Khaled Amara,1 Johanna Steen,1 Fiona Murray,1 Henner Morbach,2  
Blanca M. Fernandez-Rodriguez,3 Vijay Joshua,1 Marianne Engström,1 
Omri Snir,1 Lena Israelsson,1 Anca I. Catrina,1 Hedda Wardemann,4  
Davide Corti,3 Eric Meffre,2 Lars Klareskog,1 and Vivianne Malmström1
1Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet,  
SE-171 76 Solna, Stockholm, Sweden
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520
3Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland
4Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, D-10117 Berlin, Germany
Antibodies targeting citrullinated proteins (ACPAs [anticitrullinated protein antibodies]) 
are commonly found in patients with rheumatoid arthritis (RA), strongly associate with 
distinct HLA-DR alleles, and predict a more aggressive disease course as compared with 
seronegative patients. Still, many features of these antibodies, including their site of 
production and the extent of MHC class II–driven T cell help, remain unclarified. To 
address these questions, we have used a single B cell–based cloning technology to isolate 
and express immunoglobulin (Ig) genes from joint-derived B cells of active RA patients. 
We found 25% of synovial IgG-expressing B cells to be specific for citrullinated auto-
antigens in the investigated ACPA+ RA patients, whereas such antibodies were not found 
in ACPA patients. The citrulline-reactive monoclonal antibodies did not react with the 
unmodified arginine peptides, yet several reacted with more than one citrullinated anti-
gen. A role for active antigen selection of the citrulline-reactive synovial B cells was 
supported by the strong bias toward amino acid replacement mutations in ACPA+  
antibodies and by their loss of reactivity to citrullinated autoantigens when somatic 
mutations were reverted to the corresponding germline sequences.
© 2013 Amara et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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most commonly rearranged genes for both ACPA+ and ACPA 
patients (Fig. 1 a and Table S3). The distribution of IgG sub-
classes of synovial B cells was similar to that of normal human 
serum, dominated by IgG1 and IgG2 and with low numbers 
of IgG3 (Fig. 1, e and f ). When analyzing the CDR3 (com-
plementarity-determining region 3) features, there were no 
significant differences between ACPA+ and ACPA samples 
and only subtle differences in the CDR3 lengths (Fig. 1 b). In 
terms of light chain gene usage, V1, V3, and J3 were most 
commonly used among kappa clones and V1, V2, and J3 
for lambda (Fig. 1, c and d; and Table S3). Collectively, these 
results indicate that the Ig gene usage in synovial B cells from 
the inflamed joints of ACPA+ and ACPA patients display a 
similarly broad Ig gene diversity.
Citrulline-specific B cells are common in ACPA+  
but not in ACPA RA synovial fluid
Out of the 258 sequenced antibodies, we expressed 160, 93 
from ACPA+ and 67 from ACPA patient samples, using an 
Ig1 construct as previously published (Wardemann et al., 
2003; Tiller et al., 2008). Hereby, monoclonal recombinant 
human antibodies were generated and could then be assessed 
for their antigen specificity. We first studied ACPA fine specific-
ity by screening for reactivity toward the citrullinated candidate 
RESULTS AND DISCUSSION
Synovial fluid IgG+ B cells display extensive clonal diversity
Single cell sorting and subsequent recombinant expression of 
antibodies from synovial IgG+CD19+ B cells from six RA 
patients, three ACPA+ and three ACPA, was performed. 
Patient demographics are displayed in Table S1. Synovial fluid 
was shown to contain significantly lower numbers of CD19+ 
B cells as compared with peripheral blood, although many 
B cells were IgG switched and 5–15% of these cells displayed 
an early plasmablast phenotype (CD19dim/CD27high; not de-
picted). Serologically, we have previously demonstrated an 
enrichment of citrulline-specific IgG antibodies in the joints 
of ACPA+ RA patients (Snir et al., 2010) and thus postulated 
the presence of ACPA-producing B cells/plasma cells in the 
joints of such patients. After our single B cell approach, we 
could analyze the synovial B cell repertoire from the analysis 
of sequences of the variable parts of the Ig genes. Our data 
demonstrate a wide variation among the patients as well as 
among individual clones in terms of the gene usage, and over-
all, the majority of the functional Ig genes were represented 
among these IgG-expressing B cells (Fig. 1 and Table S3). 
In total, 258 IgH () and corresponding IgL gene sequences 
were generated from ACPA+ (n = 132) and ACPA (n = 126) 
patients. For the Ig heavy chain, IGHV3 and IGHJ4 were the 
Figure 1. Similar IgG gene characteristic in synovial B cells from ACPA+ and ACPA RA patients. (a) Summary of VH and JH family gene 
usage in seropositive (ACPA+) and negative (ACPA) patient samples. (b) Overview of IgH () CDR3 amino acid characteristics: length (left) and neg-
atively (middle) and positively (right) charged amino acids in ACPA+ and ACPA patients. (c and d) Light chains data depicting V/J (c) and V/J 
(d) gene family usage. (e) Distribution of IgG subclasses displayed per patient with the total number of sequences analyzed represented in the mid-
dle of the pie charts. (f) IgG subclass distribution in ACPA+ and ACPA patient samples. Differences between individual fractions were not statisti-
cally significant (P > 0.5), as determined by Fisher’s exact test.
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positive clones for one or several of the different citrullinated 
peptides. Notably, such clones were generated only from 
ACPA+ and not from ACPA patient samples (Fig. 2 a). All 
clones reacting toward citrullinated peptides failed to recognize 
RA autoantigens -enolase (CEP-1; amino acids 5–21), vimen-
tin (amino acids 60–75), and fibrinogen (amino acids 36–52). 
Overall, CEP-1 was the dominant B cell epitope recognized by 
these citrulline-specific antibodies, and we identified several 
Figure 2. Citrulline-reactive antibodies could be generated from ACPA+ but not from ACPA RA patients. (a) Pie charts summarizing the 
frequency of the citrulline-reactive clones (to any of the tested citrulline peptides) in individual patient samples. The top panel represents the three 
ACPA+ patient samples and the three in the bottom panel, the ACPA samples. The absolute number of tested antibodies is indicated in the center of 
each pie chart. (b) Frequency comparison of antigen reactivity in the clones generated from the different ACPA+ and ACPA patients (one symbol 
summarizes all generated antibodies from each individual; range 15–37 clones per patient sample; in total 93 antibodies were tested from ACPA+ and 67 
from ACPA patients). CCP denotes general citrulline reactivity; polyreactivity is based on positivity of two or more of the following: insulin,  
LPS, and double-stranded DNA; and lastly tetanus toxoid was used as a proxy for recall response. Horizontal lines represent the mean values of reac-
tivity for all RA patients. (c) ELISA graphs of the various ACPA fine specificities: CEP-1 (citrullinated -enolase, amino acids 5–21), cit-fib (citrullinated 
fibrinogen, amino acids 36–52), and cit-vim (citrullinated vimentin, amino acids 60–75). Black lines represent individual IgG+ memory B cells antibod-
ies. (c) Green lines represent the high positive control (serum pool of ACPA+ antibodies). (c and e) Red lines represent the negative control antibody 
(serum pool of ACPA antibodies). Each vertical row represents one ACPA+ patient sample. (d) ELISA graphs of the corresponding arginine versions of 
the peptides. (c–e) Dashed horizontal lines show a cutoff of OD450 for positive reactivity. (e) Sequences from four selected antibodies with high reac-
tivity to two or more of the citrullinated peptides that were subsequently reverted into their predicted germline sequence (in both the FWRs and 
CDRs) and then expressed as recombinant antibodies. ELISA graphs illustrate the citrulline reactivity of the original antibodies (i.e., mutated; left) 
compared with those encoded by the predicted germline sequences (right). Data are representative of three to six independent experiments.
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random mutations (ratio > 2.9; Shlomchik et al., 1987). R/S 
mutation ratios in the framework regions (FWRs) are, how-
ever, usually lower than in the CDRs but may have a role in 
the antibody structure (Berek et al., 1991). In our study, the 
sequences generated from cells of ACPA patients contained 
significantly more somatic mutations than those from ACPA+ 
patients (Fig. 4, a and e). The overrepresentation of mutations 
in ACPA patients could be a consequence of recycling of 
nonreactive or low-affinity B cells within the germinal centers 
(Allen et al., 2007). Interestingly, sequences generated from 
ACPA+ patient samples displayed a bias toward replacement 
mutations as compared with sequences isolated from ACPA 
patients, resulting in a striking difference in the R/S mutation 
ratios, especially in the CDR1 and CDR2 regions, which nor-
mally interact with antigens (Fig. 4, b, f, and g). These results 
suggest that antigen-driven B cell activation and somatic hy-
permutations (SHMs) are characteristic of antibodies isolated 
from ACPA+ patients. Thus, although these data provide sup-
portive evidence for an antigen-driven response, we cannot 
exclude the possibility of a concomitant component of poly-
clonal B cell stimulation in these synovial samples (Shlomchik 
et al., 1987; Randen et al., 1992; Bridges et al., 1993).
Next we performed reanalyses of the mutation patterns 
of the monoclonal antibodies generated from ACPA+ pa-
tient samples based on citrulline reactivity. As seen in Fig. 4 c, 
the citrulline-specific antibodies displayed fewer overall 
mutations but higher R/S ratios in their CDRs as compared 
the native nonmodified arginine version of the peptide (Fig. 2, 
c and d). Several clones displayed cross-reactivity to one or 
more citrulline antigens, warranting more detailed affinity 
analysis in addition to the ELISA. For this purpose, surface 
plasmon resonance (SPR) measurements were performed to 
study the kinetics of antibody–peptide interactions, and the 
analyzed citrulline-specific monoclonal antibodies were shown 
to display cross-reactivity to various citrullinated peptides with 
variable affinities. Overall, the Kd values were in micro- to 
nanomolar range for all analyzed antibodies: from 1.36 × 106 
to 5.94 × 1010 M for CEP-1, from 3.84 × 105 to 3.01 × 
109 M for cit-fib, and from 1.56 × 106 to 1.06 × 1010 M 
for cit-vim (Table S2). The antibody 1276SF-D10 showed the 
highest binding affinity for CEP-1 with a Kd = 5.94 × 1010 M 
but exhibited 20-fold and almost 400-fold lower binding af-
finities to cit-fib (Kd = 3.10 × 109 M) and cit-vim (Kd = 
1.55 × 108 M), respectively. The antibody 1103SF-B02 
showed the highest binding affinity for cit-vim with a Kd = 
1.06 × 1010 M but exhibited 3- and 100-fold lower binding 
affinities to CEP-1 (Kd = 3.03 × 109 M) and cit-fib (Kd = 
1.01 × 108 M), respectively. Many antibodies displayed low 
to medium overall binding affinity and cross-reacted to sev-
eral citrullinated antigens, whereas the antibodies with high 
binding affinity for one antigen only displayed low cross- 
reactivity to other citrullinated antigens. These observations 
suggest that several different target antigens may initially drive 
the autoimmune responses before being refined and focused 
on one particular epitope.
Next, the generated recombinant antibodies were tested 
for alternative antigen specificities, first with the RA diagnos-
tic anticyclic citrullinated peptide (anti-CCP) assay (Snir et al., 
2010) and subsequently also for polyreactivity, using a pre-
viously validated panel of ubiquitous antigens toward which 
RA and systemic lupus erythematosus patient–derived B cells 
often show reactivity (Wardemann et al., 2003; Tiller et al., 
2008), as well as for the recall antigen tetanus toxoid. Reac-
tivity to CCP was only found for antibodies derived from 
ACPA+ patients (P < 0.001), whereas polyreactivity and tet-
anus reactivity were found in both groups at similar fre-
quencies (Fig. 2 b and Table S3). However, none of the 
citrulline-reactive antibodies were cross-reactive to tetanus, 
whereas 8 out of 25 displayed polyreactivity (Table 1). Two of 
the citrulline-reactive monoclonal antibodies (1325SF-B109 
and 1276SF-D10) were used for the staining of synovial tissue 
biopsies from three RA patients to analyze the presence of 
the target antigens in the rheumatic joint. Both antibodies 
showed distinct staining of inflamed synovial tissues from RA 
patients, as exemplified in in Fig. 3, whereas staining with the 
isotype control was negative in all experiments (Fig. 3 c).
Citrulline-specific Igs display a different mutational pattern 
as compared with citrulline-negative Ig derived  
from the same inflamed joint
A signature of antigen-driven selection is represented by an 
increase in the replacement to silent (R/S) mutation ratios in 
the CDRs as compared with what would be expected for 
Figure 3. Immunohistochemical localization of citrullinated  
proteins in synovial tissues of RA patients. (a and b) Immunohisto-
chemistry using two of the recombinant citrulline-specific antibodies, 
1276SF-D10 (a) and 1325SF-B109 (b), brown staining of both the lining 
(black arrows) and sublining (white arrows) layers in an inflamed syno-
vial biopsy, obtained at the time of joint arthroplasty from a RA patient. 
(c) Staining of a matched irrelevant IgG2a-negative control used at 
similar concentration. Insets show the same samples at higher magnifi-
cation. Similar results were observed in two other RA synovial tissues 
(not depicted). Data presented in this figure are representative of three 
independent experiments from four patients. Bars, 68 µm.
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Figure 4. Citrulline-reactive antibodies display a bias toward nonsynonymous mutations in the CDRs. (a) Comparison of the absolute  
numbers of somatic mutations in individual VH, V, and V genes of the antibodies generated from ACPA+ and ACPA patients. (b) Frequencies of 
replacement (R) and silent (S) mutations in the CDRs and FWRs of VH, V, and V genes of synovial IgG+ memory B cells from ACPA+ and  
ACPA RA patients. (c) Comparison of the absolute numbers of somatic mutations between citrulline-positive versus -negative antibodies generated 
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carriage of the PTPN22 risk allele (two out of three ACPA+ 
and one out of three ACPA). ACPA+ patients were also 
selected for having high titers in the CCP test (>300, cut off 
for positivity 25). Still, our data demonstrate a considerable 
heterogeneity in the fine specificity of the citrulline-reactive 
B cells. None of the antibodies generated appeared to be 
clonally related based on the dissimilarity of the VH-DH-JH 
joints, a finding which could be explained by the many dif-
ferent candidate autoantigens that have been found to be 
targeted by ACPA in RA patients (Lundberg et al., 2012). 
Clearly, understanding the role of ACPAs in the pathogene-
sis of RA will require careful dissection of several different 
epitopes, a notion well-compatible with observations in the 
mouse, where different anticitrulline antibodies are able to 
trigger or enhance development of arthritis (Kuhn et al., 
2006; Hill et al., 2008; Uysal et al., 2009) or specific features of 
arthritis such as bone erosions (Harre et al., 2012). Extended 
studies on synovial tissue and possible differences to synovial 
fluid would also be needed to fully dissect the local contribu-
tion of B cells within the rheumatic joint.
Our study gives rise to several downstream questions 
relating to the mechanisms that determine accumulation of 
ACPA-producing B cells and plasma cells in joints and how 
and where these cells differentiate and undergo SHM. Key 
factors for driving plasma cell differentiation such as IL-6, 
IL-21, APRIL, and CXCL13 are present (and elevated) in the 
rheumatic joint (McInnes and Schett, 2007; Humby et al., 
2009), and plasma cell differentiation (without assessment of 
antigen specificity) has been demonstrated to occur in the 
rheumatic joint by extensive V gene analysis (Scheel et al., 
2011). Indeed, a subset of the IgG+ B cells we analyzed dis-
played an early plasmablast phenotype, which is indicative 
that at least some of the antibodies we have generated are also 
secreted in vivo.
Besides the role of antibodies as effector molecules in RA 
pathology, it is also tempting to speculate that the synovial 
IgG-expressing B cells specific for citrullinated autoantigens 
may function as local antigen-presenting cells important for 
T cell reactivation. Here the B and T cell epitopes may be ex-
pected to overlap, as has been shown to be the case for citrul-
linated vimentin (Verpoort et al., 2007; Snir et al., 2011). 
A similar scenario has been discussed in the context of celiac 
disease, another condition under which high numbers of 
autoantigen-specific B cells are found in the target organ 
(Di Niro et al., 2012).
In conclusion, the present findings have demonstrated the 
utility of a single cell approach for generation of monoclonal 
antibodies from the target organ of a classical autoimmune 
disease, with resulting new insights on the specificity as well 
as mutational features of the resulting IgGs. Notably, the 
with the citrulline-negative clones (Fig. 4 d). Traditionally, 
selection of high-affinity B cells during affinity maturation is 
primarily dependent on the presentation of antigens to T cells 
and takes place in germinal centers (Liu et al., 1997). How-
ever, it is known that such affinity maturation may also take 
place at extrafollicular sites (William et al., 2002). To address 
whether the citrulline-specific antibodies had undergone 
affinity-driven maturation, we reverted four antibodies with 
high citrulline reactivity to their predicted germline sequences. 
Reversion of mutations in these four citrulline-specific mono-
clonal antibodies led to a loss of reactivity to all the autoantigens 
(Fig. 2 e). The above observations suggest that the genera-
tion of citrulline-specific antibodies may result from T cell–
dependent B cell immune responses (Shlomchik et al., 1987; 
Weiss and Rajewsky, 1990; Berek et al., 1991). Moreover, 
SHM was likely required for development of high-affinity 
citrulline-binding antibodies because reversion of these four 
representative citrulline-specific antibodies to the corre-
sponding germline led to complete loss of binding to the 
citrullinated peptides.
We and others have previously postulated that auto-
immunity against citrullinated autoantigens may initially be 
triggered at sites distant from the joints, e.g., in lungs during 
smoking (Klareskog et al., 2008) or in gums during infection 
with Porphyromonas gingivalis or other bacteria (Lundberg 
et al., 2008; Berthelot and Le Goff, 2010), whereas the factors 
behind the transition to arthritis are still unclear. Our data 
provide the first evidence that specificity of IgGs of B cells 
from joints of ACPA+ RA patients can be drastically biased 
toward reactivity with the candidate citrullinated autoanti-
gens. More extensive investigations of B cell/plasma cell spec-
ificities in the blood or other lymphoid organs would be 
required to determine the degree to which this bias is caused 
by local immune reactions driven by T cells present in in-
flamed joints or whether immune activation against citrulli-
nated autoantigens also happens outside the joint. The analysis 
of SHM patterns suggests that at least antibodies generated 
from synovial fluid B cells are driven by T cell immunity. 
In this context, it is of interest that T cell responses to the 
same sets of RA-associated citrullinated autoantigens have been 
described and associate to the same set of HLA-DR alleles 
(Sebbag et al., 2006; James et al., 2010; Snir et al., 2011; Pieper 
et al., 2012).
RA patients are known to display a B cell repertoire gen-
erally biased toward autoimmunity (Samuels et al., 2005; 
Menard et al., 2011), and some underlying factors have been 
identified such as increased frequency of the C1858T PTPN22 
risk allele in ACPA+ RA patients (Menard et al., 2011). Our 
patient samples were selected and characterized concerning 
the presence of the RA-associated HLA-DRB1 alleles and 
from ACPA+ patients. (d) R/S mutation ratios in the CDRs and FWRs of the VH, V, and V genes in the citrulline-positive and -negative clones gener-
ated from ACPA+ patients. (e) Absolute numbers of somatic mutations in individual VH and IgL genes of the antibodies generated from the individual  
patient samples. (a, c, and e) Horizontal bars indicate mean. (f and g) Frequencies of R and S mutations in the CDRs and FWRs of VH and VL of syno-
vial IgG+ memory B cell from the individual ACPA+ (f) and ACPA (g) RA patients. The R/S ratios are indicated below the respective graphs.
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for each region based on the absolute number of nucleotides in all analyzed 
sequences as defined by IgBLAST. IgG isotype subclasses were determined 
using the international ImMunoGeneTics database (Table S3).
Cloning and sequencing
Restriction sites for expression vector cloning were introduced by using 
gene-specific primers and first PCR products as template as previously 
described (Wardemann et al., 2003; Tiller et al., 2008). The digested PCR 
products from each single cell were cloned into expression vectors con-
taining human Ig1, Ig, or Ig constant regions as previously described 
(Wardemann et al., 2003; Tiller et al., 2008). Ligation reactions were per-
formed using the quick ligase kit (New England Biolabs, Inc.) according 
to the manufacturer’s instructions. Expression vectors containing IgH 
and the corresponding IgL genes were transformed into DH5 bacteria 
(Gibco Invitrogen) and sequentially isolated using NucleoSpin plasmid 
DNA purification kits (Macherey-Nagel) according to the manufacturer’s 
instructions. To confirm identity with the original PCR products, the 
isolated IgH and IgL plasmids from each clone were sequenced.
Antibody production and purification
Antibodies were produced by transient cotransfection of exponentially 
growing 293 human embryonic kidney fibroblasts (Gibco Invitrogen) using 
the polyethylenimine (PEI)-precipitation method as described previously 
with some modifications (Boussif et al., 1995; Mouquet et al., 2011). 
Adherent (293A) as well as suspension (Freestyle 293F) cells were used to 
generate recombinant proteins (Gibco Invitrogen). 293A cells growing in 
DMEM + GlutaMAX (Gibco Invitrogen) supplemented with 10% ultra-
low IgG FBS (Gibco Invitrogen) and antibiotics/antimycotics (Gibco Invi-
trogen) were washed at 70% cell confluency using serum-free DMEM for 
5 min. The medium was then replaced with serum-free DMEM + Gluta-
MAX supplemented with 1% Nutridoma-SP (Roche) and antibiotics/ 
antimycotics (Gibco Invitrogen) before PEI-mediated transfection with equal 
amounts (10 µg) of IgH and corresponding IgL chain vector DNA. Anti-
bodies were alternatively produced by transient transfection of suspension 
cultured 293 Freestyle cells (Gibco Invitrogen) with PEI-Max (Polysciences) 
as transfection agent and a total of 20 µg of vector DNA, as previously de-
scribed (Corti et al., 2011). Supernatants were collected after 6 d of culture, 
and antibodies were purified by binding to protein G–Sepharose (Sigma-
Aldrich) and eluted with 0.1 M glycine buffer, pH 3, into storage buffer 
(1 M Tris-HCl, pH 8). Antibody concentrations were determined by anti–
human IgG1 ELISA using human monoclonal IgG1 as standard (Sigma-
Aldrich) as previously described (Wardemann et al., 2003; Tiller et al., 
2008). Expression of antibodies consisting of both heavy and light chain, 
as well as the protein purity, was verified by PAGE.
Reversion of hypermutated sequences to germline
Antibodies for reversion experiments were chosen according to their level of 
reactivity to the citrullinated autoantigens (Table 1). Germline sequences were 
determined by reverting mutations to the germline sequence while retaining 
the original CDR3 junctions and terminal deoxynucleotidyl transferase (TdT) 
N nucleotides. Germlined VH and VL nucleotide sequences were codon op-
timized and synthesized by Genscript and their accuracies were confirmed by 
sequencing. Recombinant mutated and germline-reverted antibodies were 
tested for citrulline reactivity by ELISA as described above in comparison.
Antibody specificities
Assessment of IgG antibodies reactivity against -enolase. Anti–-
enolase reactivity was determined by ELISA as described previously with 
some modifications (Snir et al., 2010). In brief, 96-well Nunc plates were 
coated with 2.5 µg/ml of the -enolase peptide 1 in its native (REP-1) or 
citrullinated (CEP-1) form (Kinloch et al., 2005; Lundberg et al., 2008). 
Purified antibodies, diluted in blocking buffer, were used at concentrations 
of 5, 1, 0.2, and 0.04 µg/ml to generate dilution curves. Positive and negative 
controls included sera from patients and healthy individuals, respectively. In all 
ELISAs, HRP-conjugated goat anti–human IgG (Jackson ImmunoResearch 
generated antibodies will also provide the immunological/
rheumatological community the opportunity to investigate 
the role of specific immunity to citrullinated autoantigens in 
arthritis and to identify ways to counteract the emergence, as 
well as the effects, of such immunity.
MATERIALS AND METHODS
Patients
RA patients attending the Rheumatology Clinic at Karolinska University 
Hospital and fulfilling the American College of Rheumatology criteria for 
the diagnosis of RA (Arnett et al., 1988) were included in the study. In-
formed consent was obtained from all patients in accordance with a protocol 
approved by the Ethical Review Committee North (KI forskningsetikkom-
mitte Nord) of Karolinska University Hospital.
Synovial fluid samples from six HLA-DR shared epitope–positive RA 
patients (five females and one male) with a median age of 39 yr (range 35–47 
yr) and median disease duration of 10 yr (range 3–28 yr) were included. The 
joint fluid was taken at a time point of local disease activity that required 
arthrocentesis and subsequent injection of local corticosteroids.
The demographic and clinical features of all six patients are summarized in 
Table S1. In brief, three of the patients were ACPA+ based on a CCP test, 
whereas three were negative. The ACPA+ patients showed variable positivity 
for citrullinated -enolase (CEP-1; Kinloch et al., 2005; Lundberg et al., 2008), 
vimentin (amino acids 60–75), and fibrinogen (Table S1;  Verpoort et al., 2007).
Flow cytometric analysis
Mononuclear cells were prepared from synovial fluid samples by Ficoll-
Paque Plus preparation (GE Healthcare). Immunofluorescence labeling for 
flow cytometry was performed by incubating cell suspensions with anti– 
human CD19 conjugated to PE-Cy7 (BioLegend), anti–human IgG conju-
gated to APC (Miltenyi Biotec), anti–human CD3 (BioLegend) and anti–human 
CD14 (BioLegend) both conjugated to PB, anti–human CD27 conjugated 
to APC-Cy7 (BioLegend), anti–human IgD conjugated to FITC (BD), and 
anti–human IgM conjugated to PE (BioLegend). Cell incubation with anti-
bodies was performed at 4°C for 30 min in PBS/1% human serum. Flow cyto-
metric analysis was performed using a Cyan flow cytometer (Dako) and FlowJo 
software version 8.8.7 (Tree Star).
Single B cell sorting
Cryopreserved synovial mononuclear cells were thawed, and the cell suspen-
sions were stained with anti–human CD19 conjugated to PE (Miltenyi Bio-
tec), anti–human IgG conjugated to APC (Miltenyi Biotec), and anti–human 
CD3 (BD) and anti–human CD14 (BD) both conjugated to FITC. Single 
synovial B cells expressing CD19 and IgG, while lacking CD3 and CD14, 
were sorted by flow cytometry using a Cytomation MoFlo (Dako) into 
96-well PCR plates containing 5 µl/well of 0.5× PBS containing 10 mM 
DTT and 8 U RNAsin inhibitor (Promega) as previously described (Warde-
mann et al., 2003; Tiller et al., 2008).
cDNA synthesis and PCR amplification
Single cell cDNA was synthesized in a total volume of 15 µl in the origi-
nal 96-well PCR plate using the SuperScript III RT (Gibco Invitrogen). 
Individual IgH () and IgL chain ( or ) gene rearrangements were am-
plified independently, using the cDNA as template, by two successive 
rounds of PCR (50 cycles each) using primers as previously described 
(Tiller et al., 2008).
Ig gene sequence analysis
From each 96-well PCR plate, wells from which matching IgH () and Ig/
Ig amplicons were obtained were sequenced (Eurofins MWG Operon) and 
analyzed for Ig gene usage, CDR3 features, and number of V gene SHMs by 
IgBLAST comparison (Table S3). The Ig CDR3 length was determined as 
indicated previously (Kabat et al., 1983; Kabat and Wu, 1991). Replacement 
(R) and silent (S) mutation frequencies in FWRs and CDRs were calculated 
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Fc. Parallel sections were stained with irrelevant origin–, mouse monoclonal 
IgG2a isotype–, and concentration-matched antibody as negative control 
(Sigma-Aldrich). The next day, sections were first blocked with 1% normal 
goat serum and then incubated for 30 min with biotin-conjugated goat anti–
mouse secondary antibody (Invitrogen). Staining was performed using the 
VECTASTAIN Elite ABC kit (Vector Laboratories) and visualized with 3,3-
diaminobenzidine (DAB). Sections were counterstained with Mayer’s hema-
toxylin, permanently mounted, and viewed by a light microscope (Reichert 
Polyvar 2 type 302001; Leica).
SPR analysis of antibody affinities
To analyze the interactions between the citrullinated autoantigens and the 
citrulline-specific monoclonal antibodies, we performed an SPR analysis on a 
Biacore T200 (GE Healthcare) using a streptavidin capture (CAP) sensor chip 
according to the manufacturer’s instructions. Initially, Biotin CAPture reagent, 
which is a modified form of streptavidin, was immobilized on the CAP sensor 
chip for 5 min at a flow rate of 2 µl/min. Next, to immobilize the biotinylated 
citrullinated peptides on the streptavidin surface of the CAP-chip, the CEP-1 
cit-fib and cit-vim (50 nM concentrations in 0.3 M sodium phosphate buffer, 
pH 7.4) were injected for 3 min at a flow rate of 10 µl/min. Once the citrulli-
nated peptide surface on the CAP-chip was prepared, five different concentra-
tions of each of the citrulline-specific monoclonal antibodies (ranging from 
5 nM to 1.5 µM) were injected into the flow cells at a flow rate of 30 µl/min. 
For each concentration used, cycles of injection for 3 min and dissociation 
period were performed. All SPR analyses were performed at 25°C. Binding 
datasets from five different concentrations of monoclonal antibodies were 
collected using a single-cycle kinetics mode (Karlsson et al., 2006). The bind-
ing data were analyzed using the Biacore T200 Evaluation software version 
1.0 (GE Healthcare) and were fitted with a 1:1 binding model.
Statistics
Ig gene repertoire analyses, analysis of positive and negative charges in IgH 
CDR3, and antibody reactivity were calculated by Fisher’s exact test or 2 
test. Differences in CDR3 length and V gene mutations were calculated by 
paired two-tailed Student’s t test (with Wilcoxon’s signed rank test). Ratios 
of V gene SHM were calculated by one-way nonparametric Kruskal-Wallis 
test followed by Dunn’s multiple comparison tests. Differences were consid-
ered to be statistically significant at values of P ≤ 0.05. All statistical analyses 
were performed by Prism software version 5.0c (GraphPad Software).
Online supplemental material
Table S1 shows patient characteristics. Table S2 shows kinetic rates and af-
finity of synovial IgG antibodies to CEP-1, cit-fib, and cit-vim measured 
by SPR. Table S3, included as a separate Excel file, shows sequence data and 
reactivity of IgG antibodies from synovial memory B cells of RA patients. 
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20121486/DC1.
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Laboratories, Inc.) was used as the detecting antibody and visualized using 
the chromogenic substrate 3,3,5,5-tetramethylbenzidine (Bio-Rad Labo-
ratories). Reactivity was detected at 450 nm with a reference of 650 nm, and 
the minimum OD450 at which antibodies were considered reactive is indi-
cated in each graph by the red line (Fig. 2, c and e). To be considered reac-
tive, the results for any given antibody had to be confirmed in at least two 
independent experiments.
Assessment of IgG antibody reactivity against fibrinogen and 
vimentin. Anti-vimentin and -fibrinogen reactivity was determined by 
ELISA as described previously with some modifications (Snir et al., 2010). 
In brief, streptavidin-coated high binding–capacity 96-well plates (Thermo 
Fisher Scientific) were coated with 1 µg/ml of biotinylated vimentin (amino 
acids 60–75) or fibrinogen (amino acids 36–52) peptides in their native and 
citrullinated forms (Verpoort et al., 2007). All other stages of the vimentin 
and fibrinogen ELISAs were performed exactly as for the -enolase ELISA 
described above.
Anti-CCP assay. Anti-CCP reactivity was determined using a commercial 
anti-CCPlus ELISA kit according to the manufacturer’s instructions (Euro-
Diagnostica). Purified antibodies were used at concentrations of 5, 1, 0.2, 
and 0.04 µg/ml in blocking buffer. Positive and negative controls included 
sera from patients and healthy individuals, respectively. Reactivity was de-
tected at 450 nm with a reference of 650 nm, and the minimum OD450 at 
which antibodies were considered reactive is indicated in each graph. To be 
considered reactive, the results for any given antibody had to be confirmed 
in at least two independent experiments.
Assessment of IgG antibodies polyreactivity. IgG antibodies were 
screened for reactivity against specific antigens as previously described 
(Wardemann et al., 2003). Three different control antibodies were used in 
all ELISAs: mGO53 (nonreactive), JB40 (weak reactive), and ED38 (high 
reactive; Wardemann et al., 2003; Meffre et al., 2004). Antibodies were 
considered polyreactive when they recognized at least two antigens out of 
the three analyzed antigens that include double-stranded DNA, insulin, 
and LPS. In all ELISAs, HRP-conjugated goat anti–human IgG (Jackson 
ImmunoResearch Laboratories, Inc.) was used as detecting antibody and 
revealed using the chromogenic substrate 3,3,5,5-tetramethylbenzidine 
(Bio-Rad Laboratories). Reactivity was detected at 450 nm with a refer-
ence of 650 nm and the minimum OD450. To be considered reactive, the 
results for any given antibody had to be confirmed in at least two inde-
pendent experiments.
Assessment of IgG antibody reactivity against human tetanus. Anti-
tetanus antibodies were detected using a commercial anti–human tetanus 
ELISA kit according to the manufacturer’s instructions (MyBioSource). 
Purified antibodies were used at a concentration of 0.5 µg/ml. Samples were 
added to the appropriate microtiter plate wells and incubated for 20 min at 
37°C. ELISAs were developed with HRP-conjugated tetanus antigen and 
revealed using the chromogenic substrate 3,3,5,5-tetramethylbenzidine. 
Reactivity was detected at 450 nm with a reference of 650 nm and the mini-
mum OD450. To be considered reactive, the results for any given antibody 
had to be confirmed in at least two independent experiments.
Immunohistochemical analysis
Immunohistochemical staining was performed on synovial tissue sections to 
investigate the presence of citrullinated proteins. Biopsy specimens were ob-
tained from three RA patients at the time of joint replacement. Serial cryo-
sections (7 µm) were fixed for 20 min with 2% (vol/vol) formaldehyde 
(Sigma-Aldrich) and stored at 70°C until use. For the immunostaining, 
synovial tissue sections were blocked with 1% H2O2 and 20% AB human 
serum (Akademiska pharmacy) for 20 min and incubated overnight in a moist 
chamber at 4°C with the purified recombinant “murinized” antibodies 
(range 3–10 µg/ml). The murinization of the human monoclonal antibodies 
was performed by replacing the full human IgG1 Fc by the murine IgG2a 
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